I made a commitment early on that I would tear up Trump’s budget and write a new one.
Fight to protect NIH funding and biomedical research from Trump-era cuts.
Occurrences
Evidence
unverified · Source version 14728 · locator unknown
Murray said, “I fight for policies to hold giant pharmaceutical companies accountable and lower costs for all of us,” and framed health-care affordability as a central campaign issue.
unverified · Source version 14729 · locator unknown
Murray said she was “proud to have secured several significant, bipartisan funding increases for NIH over the past few years” and said she would “do everything I can to make sure we don’t take our foot off the gas here.”
unverified · Source version 14730 · locator unknown
Murray said the Trump administration’s NIH indirect-cost cap was “illegal” and would be “nothing short of catastrophic” for lifesaving research; the release says Congress’ bipartisan Labor-HHS appropriations bill prohibits modifications to NIH indirect costs.
unverified · Source version 14731 · locator unknown
Section 224 says indirect-cost rules “shall continue to apply to the National Institutes of Health” and Section 240 limits multiyear-award obligations; the NIH title appropriates major funding for NIH accounts, including $48.7 billion for NIH and $226 million for the Cures Act account in the enacted law.
unverified · Source version 5342 · locator unknown
Murray said that in the government funding bill Trump signed into law on Feb. 3, 2026, she secured $48.7 billion for NIH, a $415 million increase, and that the bill rejected the Trump administration’s proposal to cap indirect cost rates at 15% and other cuts to NIH.
unverified · Source version 16882 · locator unknown
Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.
unverified · Source version 16883 · locator unknown
In FY 2026, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) received a budget of $440.6 million. This funding was secured under H.R.7148 - Consolidated Appropriations Act, 2026.
unverified · Source version 20511 · locator unknown
Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.
unverified · Source version 20512 · locator unknown
Public Law 119-75 enacted the Consolidated Appropriations Act, 2026.
unverified · Source version 5342 · locator unknown
Murray said the February 2026 funding law she helped secure provided $48.7 billion for NIH, raised NIH funding by $415 million, rejected the Trump administration's 15% indirect-cost cap, and blocked planned cuts to biomedical research.
unverified · Source version 20511 · locator unknown
NIH's revised March 2026 policy page says that under Public Law 119-75 the indirect-cost provisions continue to apply to NIH awards.
unverified · Source version 43391 · locator unknown
During the 2026-06-09 to 2026-07-08 lookback window, The Guardian reported that a May 29 OMB proposal would put federal research grants under political-appointee control and that advocates estimated many NIH-funded trials could be discontinued if the rule took effect.
unverified · Source version 43392 · locator unknown
Axios reported that President Trump's FY 2027 budget proposed a $5 billion NIH cut after Congress had rejected the prior year's much larger NIH reduction, setting up another appropriations fight.
unverified · Source version 16883 · locator unknown
NIH's NIBIB budget page says that in FY 2026 NIBIB received $440.6 million under H.R. 7148, the Consolidated Appropriations Act, 2026, and that the money is primarily used for extramural research.
unverified · Source version 14731 · locator unknown
Public Law 119-75 appropriated FY 2026 NIH institute and center funds, including major accounts for cancer, heart/lung/blood, allergy/infectious diseases, translational sciences, the NIH Office of the Director, and NIH buildings and facilities.
unverified · Source version 14731 · locator unknown
Section 224 of Public Law 119-75 kept NIH indirect-cost rules tied to 45 CFR part 75 in place and barred using federal funds to develop or implement a modified approach to those provisions.
unverified · Source version 5342 · locator unknown
Murray said she committed to replacing Trump's budget, won more than a $415 million NIH increase, blocked the indirect-cost cap, rejected the proposed 40 percent medical-research cut, and made Trump sign the funding bill into law.
unverified · Source version 64242 · locator unknown
Sec. 157. (a) Notwithstanding section 106, through December 11, 2026, a rule to revise the Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (commonly known as the ``Uniform Guidance''), arising out of the notice of proposed rulemaking titled ``Regulation for Federal Financial Assistance'', which was published in the Federal Register on May 29, 2026, or a substantially similar rule, shall not be issued or finalized.
verified · Source version 64242 · locator 1563
Such amounts as may be necessary, at a rate for operations as provided in the applicable appropriations Acts for fiscal year 2026 and under the authority and conditions provided in such Acts
verified · Source version 64244 · locator 2736
This outrageous agreement must be terminated immediately, and we need Republicans in Congress to join us in using their power to ensure that happens.
unverified · Source version 64226 · locator unknown
I’m going to fight this corrupt heist every step of the way.
unverified · Source version 64246 · locator unknown
Efforts include more than $88 million in funding for biomedical infrastructure projects nationwide
unverified · Source version 64248 · locator unknown
Sens. Susan Collins and Patty Murray are rejecting efforts by the Trump administration to give the White House control of National Institutes of Health grant funding.
Assessments
Murray was a sitting U.S. senator when the FY 2026 Consolidated Appropriations Act was enacted on February 3, 2026. The evidence ties her appropriations work to $48.7 billion for NIH, a $415 million increase, rejection of the Trump administration's proposed NIH cuts, and preservation of NIH indirect-cost protections against the proposed 15% cap. Later FY 2027 threats show the broader fight continued, but the promised protection from the cited Trump-era NIH cuts was materially achieved during the same Senate term.
The record shows Murray materially helped secure enacted FY 2026 appropriations that increased NIH funding, preserved indirect-cost protections, and blocked the Trump administration's proposed NIH cuts. Because the outcome was codified in law while she was serving as U.S. Senator, this counts as delivered in the same term.
Patty Murray, while serving in the Senate, publicly and legislatively pushed back on the Trump-era NIH indirect-cost cap and other proposed cuts, and the FY 2026 appropriations law she highlighted enacted NIH funding increases while keeping indirect-cost protections in place. Because the outcome was secured in her current Senate term and the record ties her to the enacted result, this counts as fulfilled rather than merely aspirational.
Congress enacted the Consolidated Appropriations Act, 2026 (P.L. 119-75) on Feb 3, 2026, which appropriated $48.7 billion for NIH and included statutory language (e.g., Section 224 and related NIH title provisions) preserving existing NIH indirect-cost protections and rejecting the Trump administration's proposed indirect-cost cap. NIH budget pages and the NIH grants policy statement reflect these enacted protections and FY2026 funding. Senator Murray publicly linked her efforts to securing the funding and blocking the proposed cuts in a Senate press release and had previously campaigned and spoken against the administration's proposal, indicating she materially advanced this outcome while in office. On that basis the promise to fight to protect NIH funding and biomedical research from Trump-era cuts is fulfilled in the same Senate term.
The promise was to fight to protect NIH funding and biomedical research from Trump-era cuts. During Murray's same Senate term, the FY 2026 appropriations law was enacted with substantial NIH funding, reportedly $48.7 billion, including an increase, and it preserved protections against the Trump administration's proposed indirect-cost cap and related cuts. Murray was an active federal officeholder, publicly opposed the proposed cuts, and claimed credit for securing the NIH funding and blocking the indirect-cost changes in the enacted government funding bill. Because the promised protection became law during her current term and the evidence ties her materially to the outcome, this counts as delivered. The effort badge is warranted because the record shows active legislative and public advocacy, not merely passive support.
Murray promised to fight to protect NIH funding and biomedical research from Trump-era cuts. The enacted Feb. 3, 2026 federal funding law provided $48.7 billion for NIH, increased funding by $415 million, and rejected key Trump administration cut proposals including the 15% indirect-cost cap. Evidence ties Murray directly to securing the NIH funding and blocking those cuts while she remained in federal office, so the promise was delivered in the same term. The effort badge is warranted because she actively opposed the proposed cuts and materially advanced the enacted appropriations outcome.